Dr Reddy's Laboratories Ltd today announced the launch of anti-fungal ointment nystatin and triamcinolone acetonide in the US market.
In a BSE filing, Dr Reddy's Laboratories Ltd said, "It has launched nystatin and triamcinolone acetonide cream USP, in the United States market, approved by the US Food and Drug Administration (USFDA)."
The product is the generic equivalent of nystatin and triamcinolone acetonide cream, USP 1,00,000 units/g-0.1 per cent manufactured by Taro Pharmaceuticals USA Inc, it added.
Quoting IMS Health sales data, Dr Reddy's Laboratories said that for the 12-month period ending October 2016, the generic had US sales of around USD 119 million.
Dr Reddy's Laboratories' shares today were trading at Rs 3,178.70 in the morning trade on the BSE, down 0.03 per cent.
Disclaimer: No Business Standard Journalist was involved in creation of this content
